Company Overview
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.12.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +788.27% |
| 6 Months: | -33.04% |
| 3 Months: | -23.74% |
| 1 Month: | -0.90% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.14 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 36.0% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ERAS Erasca, Inc. R2KR3KPHARMA | 14.39 | -15.15 | $5.03B | 0.00% | -38.33% | -78.25% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | -7.28M | -11.16M | -19.61M | -28.18M | -46.04M | -36.51M | -35.91M | -36.96M | -37.02M | -35.97M | -34.66M | -38.85M | -67.78M | -37.24M | -35.63M | -38.12M | -34.55M | -187.91M |
| Net Income | -23.66M | -5.49M | -10.61M | -18.02M | -28.21M | -46.07M | -36.46M | -35.61M | -35.49M | -33.20M | -31.78M | -30.36M | -35.02M | -63.20M | -31.20M | -30.97M | -33.88M | -30.61M | -183.44M |
| Diluted EPS | - | - | - | - | -1.20 | -0.46 | -0.31 | -0.30 | -0.29 | -0.22 | -0.21 | -0.20 | -0.23 | -0.29 | -0.11 | -0.11 | -0.12 | -0.11 | -0.60 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -109.25M | -124.88M | -247.45M | -141.53M | -179.59M | -140.91M |
| Net Income | -101.66M | -122.76M | -242.81M | -125.04M | -161.65M | -124.55M |
| Diluted EPS | - | -1.85 | -1.99 | -0.83 | -0.69 | -0.44 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 124.83M | - | 514.91M | 395.30M | 502.53M | 396.15M |
| Current Assets | - | - | - | 444.50M | 320.68M | 308.79M | 286.24M |
| Cash & Equivalents | - | 65.38M | - | 284.22M | 93.08M | 67.74M | 73.81M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - |
| Total Liabilities | - | 17.40M | - | 103.06M | 78.61M | 79.03M | 70.98M |
| Current Liabilities | - | 13.68M | - | 48.69M | 26.16M | 31.39M | 28.51M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 55.10M | 55.86M | 51.89M | 47.14M |
| Total Equity | -13.60M | -113.98M | - | 411.85M | 316.69M | 423.50M | 325.17M |
| Shares Outstanding | - | - | - | 149.33M | 151.46M | 283.22M | 284.16M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -32.69M | -79.60M | -103.26M | -101.22M | -109.42M | -95.45M |
| Investing Cash Flow | -71.20M | -64.59M | -71.08M | -91.22M | -156.62M | 100.42M |
| Financing Cash Flow | 139.99M | 439.40M | 98.08M | 1.29M | 240.70M | 1.10M |
| Capital Expenditure | -947.00K | -11.21M | -14.55M | -1.77M | -60.00K | -128.00K |
| Free Cash Flow | -33.63M | -90.81M | -117.81M | -102.99M | -109.48M | -95.58M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 89.2% | - | -59.0% | -39.5% | -38.2% | -38.3% |
| ROCE % | -98.3% | - | -53.1% | -38.3% | -38.1% | -38.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 7.14% | 24.98M | $400.35M |
| 2 | T. Rowe Price Investment Management, Inc. | 6.06% | 21.19M | $339.61M |
| 3 | Blackrock Inc. | 6.05% | 21.15M | $339.10M |
| 4 | RTW Investments LP | 5.13% | 17.95M | $287.69M |
| 5 | Venrock Adviser, LLC | 5.12% | 17.89M | $286.81M |
| 6 | State Street Corporation | 3.48% | 12.18M | $195.32M |
| 7 | Logos Global Management LP | 3.47% | 12.15M | $194.76M |
| 8 | Vanguard Capital Management LLC | 3.26% | 11.40M | $182.78M |
| 9 | Siren, L.L.C. | 3.26% | 11.40M | $182.71M |
| 10 | Paradigm Biocapital Advisors LP | 2.73% | 9.55M | $153.09M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ERAS
Erasca (ERAS) Stock Looks Above Fair Value After Its 5x Run - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQUF83bWtVbDhEM193UzRiWVMtaGxnSHRfN0NEXzVjOFZxZHFLS29ldF9HMFZ2cEw2X2NtUk10aUktYjZwMnJLcnVNSi00UzBpd0E3V0Nod3BCazhPSEtBYl82U0NoaWR3RUVUTFlzT0I1SmZTY2g5V2ZLbmVUX2V2N2xNZW5sVGVaQW5tdV…
Leadership Change Could Reset The Case For Erasca (ERAS) Stock - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxQQmFLTmlydElBdVB2OGFrd2xBSW1iWFhvV0pzUkZSZUVxSmpSVVREUkxkamhNbEhTMVpnUzZybjBOVDNiT1ZnQmppT2FaVUF4MllWaFRwVFVRQzV5VVVBWXNBeUNlc2gycEZlZld1T0RQY3JEYUxRdzVsWmo2UzdJUmthUFMyS0NMLUlpek…
Erasca hits ‘home run’ with cancer data as analyst suggests stock drop prompted by patient death - Fierce Biotech
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNRHpFUnQxMVZabG5PTlo4cG9wZXdwUkY1YkN0NnhHZjh4bHZxeEFZQWh2dlRzYmpTVXJjVkV4dDZ6OTNEVno0Umo0SnpCM3cxNGpwMWIybVRHQjhybmJ5TjZEb3BhcFJOYWo4ckcxaGZXTWtzTE5YUm9sUU9hdTRkVmtBdWRQbGFmRVdEaU…
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQRDdRZktna0ZienNMdzI4ZkFpaFpCZ05HM2NSakZkQWhSWjJDOTFyMmNrUndQRXRjbWV0MnRINEV3NHI5cHlDSmdhd2hOcUVjWlNGcUdYT2Y4cWlUQ0lRcTdnckNrbENKSkhsd2ZIdjVJMDJtT2EtYndyN3lSS3pYMGNzX1RaRnJYMmdOQW…
Here is Why Erasca (ERAS) is One of the Best Growth Stocks Under $20 - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxOekNzaHYta3lvQ2ZJT0tVcDBXXzNqTmJoNnVWVHlKdEZZSm5Tdlk3RFhnaHM0MkRiZThNMDBnSkU0bG5QSWRSNUJjUFNUMzlyLVdiWWlIQ25WOFppUnhXQ2JKLWZjel8xc05Kd3RwcjJnMlZFUjh0dWRodmR5Q0ZkMklrRkx1dTRHbk44YX…
$ERAS stock is up 12% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPSy1ZREhCcHpZb3RIUHpnOXY0VE51UExGTnlyRk1hWFhwc2RYaWE3UlRqODR2amhsTnZCSUtqQ1Z6cnBReGMzb0xwWXZ6Mk5mR09idkpNelZOQ2RtVFpPNEhkQXRQQ2VnVlBtN1ZUQWk1NEFQdzJRMTNBZS05em1hdU1OYUo0Nm16Q0VKbE…
ERAS — Frequently Asked Questions
What is the current share price of Erasca, Inc. (ERAS)?
As of 2026-10-23 16:27 PDT, Erasca, Inc. (ERAS) trades at $14.39 on NasdaqGS. Its 52-week range is $1.43 to $22.47.
What is the market capitalisation of ERAS?
Erasca, Inc. (ERAS) has a market capitalisation of $5.03B on NasdaqGS.
What is the P/E ratio of ERAS?
ERAS trades at a trailing price-to-earnings (P/E) ratio of -15.15. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 13.84.
What is the return on equity (ROE) of ERAS?
ERAS has a return on equity (ROE) of -78.25%. Its return on capital employed (ROCE) is -38.33%.
Is ERAS a good stock to buy?
This page provides a data-driven analysis of Erasca, Inc. (ERAS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.